David I. Stirling

DFO Management /Private Equity/ (DFO) is a private equity subsidiary of MSD Capital Management LLC founded in 1998 by Glenn Robert Fuhrman and John Cartwright Phelan. The firm is headquartered in New York.

FORMA Therapeutics, Inc. discovers and develops medicines for cancer and other genetically driven diseases. Its drug discovery engine deploys screening and structure-based approaches across broad families of targets involved in tumor metabolism, epigenetics, protein homeostasis, and protein-protein interactions. The company was founded by Steven Tregay, Nikolai Kley, Stuart L. Schreiber, Todd R. Golub, Michael Foley and Alexis Borisy in 2008 and is headquartered in Watertown, MA.

Navitor Pharmaceuticals, Inc. develops medicine for age-related diseases. Its drug discovery platform targets mTORC1, which responds to and integrates the cell’s response to nutrient availability and plays a key role in protein synthesis and cellular growth. The company was founded by Alan L. Crane, David Sabatini and David Goldfarb and is headquartered in Cambridge, MA.

Founded in 1898, Northeastern University is a private research university located in the heart of Boston. Northeastern teaches worldwide experiential learning, urban engagement, and interdisciplinary research that meets global and societal needs. The University offers a range of undergraduate and graduate programs leading to degrees through the doctorate in nine colleges and schools.

The Leukemia & Lymphoma Society, Inc. operates as the world's largest voluntary health organization dedicated to funding blood cancer research, education and patient services. The firm provides treatment for , lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. It identifies and funds the most promising blood cancer research projects and forges partnerships with academic institutions, biotechnology and pharmaceutical companies to accelerate the development of new therapies. The company is headquartered in Rye Brook, NY.

TheraVasc, Inc. operates as a pharmaceutical company. It develops treatments for various chronic medical diseases and drugs for unserved vascular disease markets. The company was founded by Anthony Giordano, Christopher Kevil and James Douglas Boudreaux in 2008 and is headquartered in Cleveland, OH.

Anokion SA provides technology for retraining white blood cells to induce therapeutic immune tolerance. The firm?s approach to antigen-specific immune tolerance can be translated to virtually any protein in numerous clinical indications. The company was founded by Jerffery Hubbell, Melody Swartz, Stephan Kontos, Oscar Buset, Kristen M. Lorentz and David A. Lowin and is headquartered in Ecublens, Switzerland.

Kanyos Bio, Inc. engages in the provision of immune tolerance technology solutions. It develops antigen-specific for treatment of type-1 diabetes and celiac disease. The company was founded by Jeffrey Hubbell, Stephan Kontos, Oscar Buset, Kristen M. Lorentz, and David A. Lowin in 2015 and is headquartered in Cambridge, MA.

Torque Therapeutics, Inc. develops immunotherapies to address cancers focused on the specific modulation of immune cell subsets. The company was founded by Bart Henderson, Ulrik B. Nielsen, Darrell J. Irvine, and Thomas Lars Andresen and is headquartered in Cambridge, MA.

Helio Vision, Inc. operates as a biotechnology company. It develops a therapy for fibroproliferative disorders that lead to abnormal scarring and blindness after retina surgery. The company was founded by Josef H. von Rickenbach, Dean Eliott and Tomasz P. Stryjewski in 2016 and is headquartered in Waltham, MA.

Palleon Pharmaceuticals, Inc. operates as biotechnology company. The firm discovers and develops immuno-oncology drugs, medicines, and therapies for the treatment of cancer diseases. It specializes in clinical development, and glyco-immune checkpoint inhibitors. The company was founded by Jim Broderick, Carolyn Bertozzi and Paul Crocker in 2015 and is headquartered in Waltham, MA.

Cygnal Therapeutics, Inc. develops drugs for cancer, immunological diseases and regenerative processes. The company was founded by Noubar Afeyan, Avak Kahvejian and Jordi Mata-Fink in 2017 and is headquartered in Cambridge, MA.

ARS Pharmaceuticals, Inc. develops epinephrine nasal sprays for treatment of severe allergic reactions to food, medication, and insect bites. The company was founded by Richard E. Lowenthal, Sarina Tanimoto and Robert Bell and is headquartered in San Diego, CA.

Dren Bio, Inc. operates as a biotechnology company. It focuses on protein engineering technologies for depletion of cells, protein aggregates, and other disease-causing agents. The company was founded by John Wesley and Nenad Tomasevic in 2019 and is headquartered in San Carlos, CA.

Tranquis Therapeutics, Inc. discovers and develops novel immuno-therapeutics for neurological diseases. It offers treatment for central nervous system (CNS) disorders, including Amyotrophic Lateral Sclerosis, Parkinson 's disease, Alzheimer?s Disease, and age-related neuropathology. The company was founded by Chih-Ping Liu and Khoa D. Nguyen in June 2016 and is headquartered in Menlo Park, CA.

SR One Capital Management LP (SR One) is a venture capital firm founded in 2020. The firm is headquartered in Redwood, California.

TEN63 Therapeutics provides drug development services. The American company was founded by Nancy Miller-Rich, Marcel Frenkel, Mark Hallen, Bruce Donald. Marcel Frenkel has been the CEO since incorporation.

Attralus, Inc. operates as a biopharmaceutical company. The firm focuses on illuminating the systemic nature of amyloidosis and creating transformative medicines to improve the lives of patients. The company was founded by Jonathan Wall in 2019 and is headquartered in San Francisco, CA.

Trishula Therapeutics, Inc. is a company solely dedicated to developing TTX-030, a first-in-class anti-CD39 antibody aimed at improving outcomes for people with cancer. Trishula Therapeutics is based in South San Francisco, CA. The company's leadership, board of directors, scientific advisory board, investors, and partners are all committed to this goal. Anil Singhal has been the CEO of the company since 2021.

Sonata Therapeutics, Inc. is a pioneering private company based in Cambridge, MA that designs single therapeutics to reprogram diseased cells and create curative microenvironments. The company's machine learning-based platform identifies novel insights, targets, and therapeutics across a wide range of disease areas, with a growing pipeline of small molecule drugs and genetic therapeutics. In oncology, Sonata's transformative therapies reprogram cancer cells to release curative signals that reverse immune cell suppression and blockade, empowering the immune system to holistically eradicate tumors and drive cure. Sonata Therapeutics is creating a new class of network medicines™ designed to modulate all the key cell types in a disease microenvironment required to drive disease resolution. The company is also exploring additional therapeutic areas such as fibrosis and tissue regeneration where multicellular networks play a key role. The company has subsidiaries in the United States. The company was founded in 2022 by flagship pioneering, and the CEO is Volker Herrmann.